+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice



Phenolphthalein induces thymic lymphomas accompanied by loss of the p53 wild type allele in heterozygous p53-deficient (+/-) mice



Toxicologic Pathology 25(6): 533-540



Epidemiology studies have indicated that many human cancers are influenced by environmental factors. Genetically altered mouse model systems offer us the opportunity to study the interaction of chemicals with genetic predisposition to cancer. Using the heterozygous p53-deficient (+/-) mouse, an animal model carrying one wild type p53 gene and one p53 null allele, we studied the effects of phenolphthalein on tumor induction and p53 gene alterations. Earlier studies showed that phenolphthalein caused carcinogenic effects in Fisher 344 rats and B6C3F1 mice after a 2-yr dosing period (Dunnick and Hailey, Cancer Res. 56: 4922-4926, 1996). The p53 (+/-) mice received phenolphthalein in the feed at concentrations of 200, 375, 750, 3,000, or 12,000 ppm (approximately 43, 84, 174, 689, or 2,375 mg/kg body weight/day or 129, 252, 522, 2,867, or 7,128 mg/m2 body surface area/day) for up to 6 mo. A target organ cancer site that accumulated p53 protein in the B6C3F1 mouse (i.e., thymic lymphoma) was also a target site for cancer in the p53 (+/-) mouse. In the p53 (+/-) mouse, treatment-related atypical hyperplasia and malignant lymphoma of thymic origin were seen in the control and dosed groups at a combined incidence of 0, 5, 5, 25, 100, and 95%, respectively. Twenty-one of the thymic lymphomas were examined for p53 gene changes, and all showed loss of the p53 wild type allele. Chemical-induced ovarian tumors in the B6C3F1 mouse showed no evidence for p53 protein accumulation and did not occur in the p53 (+/-) mouse. The p53-deficient (+/-) mouse model responded to phenolphthalein treatment with a carcinogenic response in the thymus after only 4 mo of dosing. This carcinogenic response took 2 yr to develop in the conventional B6C3F1 mouse bioassay. The p53-deficient (+/-) mouse is an important model for identifying a carcinogenic response after short-term (< 6 mo) exposures. Our studies show that exposure to phenolphthalein combined with a genetic predisposition to cancer can potentiate the carcinogenic process and cause p53 gene alterations, a gene alteration found in many human cancers.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 046973326

Download citation: RISBibTeXText

PMID: 9437796


Related references

Phenolphthalein Induces Thymic Lymphomas Accompanied by Loss of the p53 Wild Type Allele in Heterozygous p53-Deficient () Mice. Toxicologic Pathology 25(6): 533-540, 1997

Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Toxicological Sciences 60(2): 264-270, 2001

Chromosome 11 loss from thymic lymphomas induced in heterozygous Trp53 mice by phenolphthalein. Toxicological Sciences 64(2): 281-282, 2001

Mechanisms for differential loss of the wild-type Trp53 allele in tumors induced in the heterozygous p53 deficient mouse. Toxicologic Pathology 29(Suppl.): 226-227, 2001

Mechanism for the induction of loss of heterozygosity of p53 gene in radiation-induced thymic lymphomas from p53 heterozygous mice. Journal of Radiation Research 41(4): 442, 2000

Allelic loss analysis of lymphomas induced in Fas-heterozygous deficient mice. Journal of Veterinary Medical Science 66(1): 97-102, 2004

Carcinogen induced loss of the wildtype p53 allele in tumors from heterozygous p53 deficient mice. Proceedings of the American Association for Cancer Research Annual Meeting 39: 562, 1998

Differential loss of the wildtype Trp53 allele in chemically induced tumors in heterozygous p53 deficient mice. Environmental and Molecular Mutagenesis 31(Suppl. 29): 66, 1998

Analysis of allele loss regions in chromosomes 9,10,12 in radiation mammary carcinogenesis of Atm and p53 heterozygous deficient mice. Journal of Radiation Research 44(4): 399, 2003

Heterozygous PPARgamma deficient mice showed higher blood pressure and more neointimal formation in response to cuff injury than wild-type mice. Diabetes 52(Suppl. 1): A177, 2003

Heterozygous p53-deficient (+/-) mice develop fewer p53-negative preneoplastic focal liver lesions in response to treatment with diethylnitrosamine than do wild-type (+/+) mice. Cancer Letters 207(2): 149-155, 2004

Bioassay of mannitol and caprolactam and assessment of response to diethylnitrosamine in heterozygous p53-deficient (+/-) and wild type (+/+) mice. Archives of Toxicology 75(1): 52-58, 2001

Bcl11b heterozygous mice are susceptible to N-methyl-N-nitrosourea-induced thymic lymphomas. Acta Medica et Biologica 55(2): 55-60, 2007

Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10(9): 1717-1723, 1995

Development of thymic lymphomas in mice disrupted of Brca2 allele in the thymus. Experimental and Molecular Medicine 40(3): 339-344, 2008